EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report

Xavier Pepin iD, Sumit Arora iD, Luiza Borges, Mario Cano-Vega, Tessa Carducci, Parnali Chatterjee, Grace Chen, Rodrigo Cristofoletti, André Dallmann iD, Poonam Delvadia iD, Jennifer Dressman, Nikoletta Fotaki und 28 weitere

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00526 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Xavier Pepin und 39 weiteren Autor:innen. Beteiligte Einrichtung: Regulatory Affairs, Simulations Plus Inc., 42505 10th Street West, Lancaster, California 93534-7059, United States. Hauptthemen laut MEDLINE: Biopharmaceutics, Models, Biological. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, Center for Drug Evaluation and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Article shares the proceedings from the August 29th, 2023 (day 1) workshop "Physiologically Based Biopharmaceutics Modeling (PBBM) Best Practices for Drug Product Quality: Regulatory and Industry Perspectives". The focus of the day was on model parametrization; regulatory authorities from Canada, the USA, Sweden, Belgium, and Norway presented their views on PBBM case studies submitted by industry members of the IQ consortium. The presentations shared key questions raised by regulators during the mock exercise, regarding the PBBM input parameters and their justification. These presentations also shed light on the regulatory assessment processes, content, and format requirements for future PBBM regulatory submissions. In addition, the day 1 breakout presentations and discussions gave the opportunity to share best practices around key questions faced by scientists when parametrizing PBBMs. Key questions included measurement and integration of drug substance solubility for crystalline vs amorphous drugs; impact of excipients on apparent drug solubility/supersaturation; modeling of acid-base reactions at the surface of the dissolving drug; choice of dissolution methods according to the formulation and drug properties with a view to predict the in vivo performance; mechanistic modeling of in vitro product dissolution data to predict in vivo dissolution for various patient populations/species; best practices for characterization of drug precipitation from simple or complex formulations and integration of the data in PBBM; incorporation of drug permeability into PBBM for various routes of uptake and prediction of permeability along the GI tract.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiopharmaceuticsModels, BiologicalHumansSolubilityPharmaceutical PreparationsExcipientsChemistry, Pharmaceutical

Stichwörter der Autor:innen

CQAsIVIVCIVIVRPBBMbioequivalencebiopredictive dissolutionmodelingpermeabilityprecipitationsolubility

Substanzen

Pharmaceutical PreparationsExcipients

Autor:innen und Institutionen

  • Regulatory Affairs, Simulations Plus Inc., 42505 10th Street West, Lancaster, California 93534-7059, United States.
  • Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • ANVISA, SIA Trecho 5́, Guara, Brasília, Federal District 71205-050, Brazil.
  • Drug Product Technologies, Amgen Inc., Thousand Oaks, California 91320-1799, United States.
  • Analytical Commercialization Technology, Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, New Jersey 07065, United States.
  • Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland 20903-1058, United States.

ORCID-Profile: Xavier Pepin, Sumit Arora, André Dallmann, Poonam Delvadia, Claire Mackie, Maria Malamatari, Deanna Mudie, James E Polli, Christer Tannergren

Förderung

  • FDA HHS
  • Center for Drug Evaluation and Research

Zitieren

APA

Pepin, X., Arora, S., Borges, L., Cano-Vega, M., Carducci, T., Chatterjee, P., Chen, G., Cristofoletti, R., Dallmann, A., Delvadia, P., Dressman, J., Fotaki, N., Gray, E., Heimbach, T., Holte, Ø., Kijima, S., Kotzagiorgis, E., Lennernäs, H., Lindahl, A., …, & Seo, P. (2024). Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00526

Vancouver

Pepin X, Arora S, Borges L, Cano-Vega M, Carducci T, Chatterjee P, et al. Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00526

BibTeX
@article{Pepin2024,
  author = {Pepin, Xavier and Arora, Sumit and Borges, Luiza and Cano-Vega, Mario and Carducci, Tessa and Chatterjee, Parnali and Chen, Grace and Cristofoletti, Rodrigo and Dallmann, André and Delvadia, Poonam and Dressman, Jennifer and Fotaki, Nikoletta and Gray, Elizabeth and Heimbach, Tycho and Holte, Øyvind and Kijima, Shinichi and Kotzagiorgis, Evangelos and Lennernäs, Hans and Lindahl, Anders and Loebenberg, Raimar and Mackie, Claire and Malamatari, Maria and McAllister, Mark and Mitra, Amitava and Moody, Rebecca and Mudie, Deanna and Musuamba Tshinanu, Flora and Polli, James E and Rege, Bhagwant and Ren, Xiaojun and Rullo, Gregory and Scherholz, Megerle and Song, Ivy and Stillhart, Cordula and Suarez-Sharp, Sandra and Tannergren, Christer and Tsakalozou, Eleftheria and Veerasingham, Shereeni and Wagner, Christian and Seo, Paul},
  title = {Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00526}
}
Kostenlos starten →